Patents by Inventor Laurence Hylton Patterson

Laurence Hylton Patterson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190249011
    Abstract: The present invention provides di-substituted acetalanthraquinone-based compounds of the Formulae (l)-(IV) that are useful for cellular staining and for light-based detection of biological material, e.g. fluorescence-based detection of biological material. These compounds may be used in hydrolysed or non-hydrolysed form. Also provided is a fluorescent complex that comprises a nucleic acid and an acetalanthraquinone-based compound of the invention; and a method of staining a biological sample comprising cells or other biological material containing nucleic acid, which method comprises contacting the biological sample with an acetalanthraquinone-based compound of the invention. In the Formulae (l)-(IV), A and B are each independently of formula —RaCH2CH(ORb)2; or one of A and B is of formula —RaCH2CH(ORb)2 and the other one is of formula: —NRb2.
    Type: Application
    Filed: June 9, 2017
    Publication date: August 15, 2019
    Inventors: Paul James Smith, Rachel Jane Errington, Laurence Hylton Patterson, Klaus Pors, Laura Cosentino
  • Publication number: 20150268142
    Abstract: According to the invention there is provided a compound of Formula (X) in which: A is a C2-C8 alkylene group; R1, R2, R3, and R4 are independently selected from hydrogen, C1-4 alkyl, C2-4 dihydroxyalkyl in which the carbon atom attached to the nitrogen atom does not carry a hydroxyl group and no carbon atom is substituted by two hydroxyl groups, or R2 and R3 together form a C2-6 alkylene group which with the nitrogen atom to which R2 and R3 are attached forms a heterocyclic ring; X1, X2 and X3 are independently selected from hydrogen, hydroxyl, NR1—A—NR2R3R4+(Zm-)1/m, for halogeno amino, C1-4 alkoxy or C2-8 alkanoyloxy; and (Zm-)1/m is an anion of charge m; or a derivative in which the group NR1 is quaternarised.
    Type: Application
    Filed: June 5, 2015
    Publication date: September 24, 2015
    Inventors: Paul James Smith, Rachel J. Errington, Laurence Hylton Patterson
  • Patent number: 9051467
    Abstract: According to the invention there is provided a compound of Formula (I) in which: A is a C2-8 alkylene group; R1, R2, R3, and R4 are independently selected from hydrogen, C1-4 alkyl, C2-4 dihydroxyalkyl in which the carbon atom attached to the nitrogen atom does not carry a hydroxyl group and no carbon atom is substituted by two hydroxyl groups, or R2 and R3 together form a C2-6 alkylene group which with the nitrogen atom to which R2 and R3 are attached forms a heterocyclic ring; X1, X2 and X3 are independently selected from hydrogen, hydroxyl, NR1-A-NR2R3R4+(Zm?)1/m, halogeno amino, C1-4 alkoxy or C2-8 alkanoyloxy; and (Zm?)1/m is an anion of charge m; or a derivative in which the group NR1 is quaternarised.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: June 9, 2015
    Assignee: BIOSTATUS LIMITED
    Inventors: Paul James Smith, Rachel J. Errington, Laurence Hylton Patterson
  • Publication number: 20130101994
    Abstract: According to the invention there is provided a compound of Formula (I) in which: A is a C2-8 alkylene group; R1, R2, R3, and R4 are independently selected from hydrogen, C1-4 alkyl, C2-4 dihydroxyalkyl in which the carbon atom attached to the nitrogen atom does not carry a hydroxyl group and no carbon atom is substituted by two hydroxyl groups, or R2 and R3 together form a C2-6 alkylene group which with the nitrogen atom to which R2 and R3 are attached forms a heterocyclic ring; X1, X2 and X3 are independently selected from hydrogen, hydroxyl, NR1-A-NR2R3R4+(Zm?)1/m, halogeno amino, C1-4 alkoxy or C2-8 alkanoyloxy; and (Zm?)1/m is an anion of charge m; or a derivative in which the group NR1 is quaternarised.
    Type: Application
    Filed: April 8, 2011
    Publication date: April 25, 2013
    Applicant: BIOSTATUS LIMITED
    Inventors: Paul James Smith, Rachel J. Errington, Laurence Hylton Patterson
  • Patent number: 8017640
    Abstract: Compounds of the general formula (I) or (IA) in which X is H, Y is a leaving group, R1 preferably being an aromatic DNA binding subunit are prodrug analogues of duocarmycin. The compounds are expected to be hydroxylated at the carbon atom to which C is joined, by cytochrome P450, in particular by CYP1B1, expressed at high levels in tumors. The prodrug is expected to be activated preferentially in tumor cells, which it will act as a DNA alkylating agent preventing cell division.
    Type: Grant
    Filed: February 27, 2007
    Date of Patent: September 13, 2011
    Assignee: University of Bradford
    Inventors: Mark Searcey, Laurence Hylton Patterson
  • Patent number: 7626026
    Abstract: Compounds of the general formula (I) or (IA) in which X is H, Y is a leaving group, R1 and optionally also R3 preferably being an aromatic DNA binding subunit are prodrug analogues of duocarmycin. The compounds are expected to be hydroxylated at the carbon atom to which X is joined, by cytochrome P450, in particular by CYP1B1, expressed at high levels in tumors. The prodrug is expected to be activated preferentially in tumor cells, where it will act as a DNA alkylating agent preventing cell division.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: December 1, 2009
    Assignee: University of Bradford
    Inventors: Mark Searcey, Laurence Hylton Patterson
  • Patent number: 7605280
    Abstract: There is disclosed a compound of formula (I) wherein each of X1 and X2 are independently NH-A-NR1R2, and wherein A is A C2-8 alkylene and R1 and R2 are independently selected from hydrogen, C1-4 alkyl, C2-4 hydroxy-alkyl and C2-4 aminoalkyl, or R1 and R2 together form a C2-6 alkylene group which with the nitrogen atom to which R1 and R2 are attached forms a heterocyclic ring, or an N-oxide derivative thereof, and wherein the compound (I) or its N-oxide derivative is optionally in the form of an acid salt derived from an organic or inorganic acid. Also disclosed is a method of its production and its uses, including its use in analyzing a cell or biological material and detecting the emitted fluorescence signal.
    Type: Grant
    Filed: March 6, 2006
    Date of Patent: October 20, 2009
    Assignee: Biostatus Limited
    Inventors: Paul James Smith, Laurence Hylton Patterson
  • Publication number: 20090233966
    Abstract: Compounds of general formula (I) or a salt thereof in which R1 is preferably an aromatic DNA binding subunit are oxidation-activated prodrugs. The compounds are expected to be converted into an epoxide at the alkene to which R2 is attached by cytochrome P450, in particular CYPIBI, expressed at high levels in tumours. R3 preferably comprises a Nitrogen mustard to provide a prodrug which has 2 alkylating groups. The prodrugs are expected to be activated preferentially in tumour cells.
    Type: Application
    Filed: March 16, 2006
    Publication date: September 17, 2009
    Applicant: School of Pharmacy, University of London
    Inventors: Mark Searcey, Laurence Hylton Patterson, Klaus Pors, Maxwell Casely-Hayford
  • Patent number: 7557215
    Abstract: Anthraquinone compounds of the general formula (I) or a salt thereof (Formula I) in which R1 to R4 are each selected from the group consisting of H, C1-4 alkyl, X1, —NHR0N (R5)2 in which R0 is a C1-12 alkanediyl and each R5 is H or optionally substituted C1-4 alkyl, and a group of formula (II) in which at least one of R6, R7 and R8 is selected from X2, and X2 substituted C1-4 alkyl and any others are H or C1-4 alkyl; R9 is selected from H, C1-4 alkyl, X2 and X2 substituted C1-4 alkyl; m is 0 or 1; n is 1 or 2; X1 is a halogen atom, a hydroxyl group, a C1-6 alkoxyl group, an aryloxy group or an acyloxy group; and X2 is a halogen atom, a hydroxyl group, a C1-6 alkoxyl group, an aryloxy group or an acyloxy group; provided that at least one of R1 to R4 is a group of formula (II). The N-oxides are useful prodrugs which are selectively bioreduced in hypoxic tumours to the corresponding cyclic amine derivatives.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: July 7, 2009
    Assignee: Somanta Limited
    Inventors: Laurence Hylton Patterson, Klaus Pors, Paul Henry Teesdale-Spittle
  • Publication number: 20080027107
    Abstract: Anthraquinone compounds of the general formula (I) or a salt thereof (Formula I) in which R1 to R4 are each selected from the group consisting of H, C1-4 alkyl, X1, —NHR0N (Rs)2 in which R° is a C1l12 alkanediyl and each R5 is H or optionally substituted C14 alkyl, and a group of formula (11) in which at least one of R6,R7 and R8 is selected from X2 , and X2 substituted C1-4 alkyl and any others are H or C14 alkyl; R9 is selected from H, C14 alkyl, X2 and X2 substituted C1-4 alkyl; m is 0 or 1; n is 1 or 2; X1 is a halogen atom, a hydroxyl group, a C1.6 alkoxyl group, an aryloxy group or an acyloxy group; and X2 is a halogen atom, a hydroxyl group, a C16 alkoxyl group, an aryloxy group or an acyloxy group; provided that at least one of R1 to R4 is a group of formula (II). The N-oxides are useful prodrugs which are selectively bioreduced in hypoxic tumours to the corresponding cyclic amine derivatives.
    Type: Application
    Filed: December 22, 2004
    Publication date: January 31, 2008
    Inventors: Laurence Hylton Patterson, Klaus Pors, Paul Henry Teesdale-Spittle
  • Patent number: 7276537
    Abstract: A compound of formula (I): in which A is a C alkylene group with a chain length between NH and N(O)R?R? of at least 2 carbon atoms and R? and R? are each separately selected from C1-4 alkyl groups and C2-4 hydroxyalkyl and C2-4 dihydroxyalkyl groups, or R? and R? together are a C2-6 alkylene group, is formulated so that upon dissolution in aqueous solution the pH of the solution is in the range of 5 to 9. The compound may be in the form of salt with a physiologically acceptable acid having a pKa in the range of ?3.0 (minus 3.0) to 9.
    Type: Grant
    Filed: May 15, 2006
    Date of Patent: October 2, 2007
    Assignee: BTG International Limited
    Inventors: William Alexander Denny, Laurence Hylton Patterson, Gavin William Halbert, Steven John Ford
  • Patent number: 7192977
    Abstract: Compounds of the general formula (I) or (IA) in which X is H, Y is a leaving group, R1 preferably being an aromatic DNA binding subunit are prodrug analogues of duocarmycin. The compounds are expected to be hydroxylated at the carbon atom to which X is joined, by cytochrome P450, in particular by CYP1B1, expressed at high levels in tumors.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: March 20, 2007
    Assignee: School of Pharmacy
    Inventors: Mark Searcey, Laurence Hylton Patterson
  • Patent number: 7179921
    Abstract: Compounds of the general formula I or IA or a salt in which X is H, Y is a leaving group, R1 preferably being an aromatic DNA binding subunit are prodrug analogues of duocarmycin. The compounds are expected to be hydroxylated at the carbon atom to which X is joined, by cytochrome P450, in particular by CYP1B1, expressed at high levels in tumours.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: February 20, 2007
    Assignee: School of Pharmacy, University of London
    Inventors: Mark Searcey, Laurence Hylton Patterson
  • Patent number: 7074835
    Abstract: A compound of formula (I): in which A is a C alkylene group with a chain length between NH and N(O)R?R? of at least 2 carbon atoms and R? and R? are each separately selected from C1-4 alkyl groups and C2-4 hydroxyalkyl and C2-4 dihydroxyalkyl groups, or R? and R? together are a C2-6 alkylene group, is formulated so that upon dissolution in aqueous solution the pH of the solution is in the range of 5 to 9. The compound may be in the form of salt with a physiologically acceptable acid having a pKa in the range of ?3.0 (minus 3.0) to 9.
    Type: Grant
    Filed: March 17, 2003
    Date of Patent: July 11, 2006
    Assignee: BTG International Limited
    Inventors: William Alexander Denny, Laurence Hylton Patterson, Gavin William Halbert, Steven John Ford
  • Patent number: 7060427
    Abstract: There is disclosed a compound of formula (I) wherein each of X1 and X2 are independently NH—A—NR1R2, and wherein A is A C2-8 alkylene and R1 and R2 are independently selected from hydrogen, C1-4 alkyl, C2-4 hydroxy-alkyl and C2-4 aminoalkyl, or R1 and R2 together form a C2-6 alkylene group which with the nitrogen atom to which R1 and R2 are attached forms a heterocyclic ring, or an N-oxide derivative thereof, and wherein the compound (I) or its N-oxide derivative is optionally in the form of an acid salt derived from an organic or inorganic acid. Also disclosed is a method of its production and its uses, including its use in analyzing a cell or biological material and detecting the emitted fluorescence signal.
    Type: Grant
    Filed: August 12, 2002
    Date of Patent: June 13, 2006
    Assignee: Biostatus Limited
    Inventors: Paul James Smith, Laurence Hylton Patterson
  • Publication number: 20040157880
    Abstract: Compounds of the general formula I or IA or a salt in which X is H, Y is a leaving group, R1 preferably being an aromatic DNA binding subunit are prodrug analogues of duocarmycin. The compounds are expected to be hydroxylated at the carbon atom to which X is joined, by cytochrome P450, in particular by CYP1B1, expressed at high levels in tumours. The prodrug is expected to be activated preferentially in tumour cells, where it will act as a DNA alkylating agent preventing cell division.
    Type: Application
    Filed: March 29, 2004
    Publication date: August 12, 2004
    Inventors: Mark Searcey, Laurence Hylton Patterson
  • Publication number: 20040157873
    Abstract: Compounds of the general formula (I) or (IA) in which X is H, Y is a leaving group, R1 and optionally also R3 preferably being an aromatic DNA binding subunit are prodrug analogues of duocarmycin. The compounds are expected to be hydroxylated at the carbon atom to which X is joined, by cytochrome P450, in particular by CYP1B1, expressed at high levels in tumours. The prodrug is expected to be activated preferentially in tumour cells, where it will act as a DNA alkylating agent preventing cell division.
    Type: Application
    Filed: April 6, 2004
    Publication date: August 12, 2004
    Inventors: Mark Searcey, Laurence Hylton Patterson
  • Publication number: 20040138246
    Abstract: Compounds of the general formula (I) or (IA) in which X is H, Y is a leaving group, R1 preferably being an aromatic DNA binding subunit are prodrug analogues of duocarmycin. The compounds are expected to be hydroxylated at the carbon atom to which X is joined, by cytochrome P450, in particular by CYP1B1, expressed at high levels in tumours. The prodrug is expected to be activated preferentially in tumour cells, where it will act as a DNA alkylating agent preventing cell division.
    Type: Application
    Filed: February 13, 2004
    Publication date: July 15, 2004
    Inventors: Mark Searcey, Laurence Hylton Patterson
  • Publication number: 20030008316
    Abstract: There is disclosed a compound of formula (I) wherein each of X1 and X2 are independently NH—A—NR1R2, and wherein A is A C2-8 alkylene and R1 and R2 are independently selected from hydrogen, C1-4 alkyl, C2-4 hydroxy-alkyl and C2-4 aminoalkyl, or R1 and R2 together form a C2-6 alkylene group which with the nitrogen atom to which R1 and R2 are attached forms a heterocyclic ring, or an N-oxide derivative thereof, and wherein the compound (I) or its N-oxide derivative is optionally in the form of an acid salt derived from an organic or inorganic acid. Also disclosed is a method of its production and its uses, including its use in analyzing a cell or biological material and detecting the emitted fluorescence signal.
    Type: Application
    Filed: August 12, 2002
    Publication date: January 9, 2003
    Applicant: BIOSTATUS LIMITED
    Inventors: Paul James Smith, Laurence Hylton Patterson
  • Patent number: 6468753
    Abstract: There is disclosed a compound of formula (I) wherein each of X1 and X2 are independently NH—A—NR1R2, and wherein A is A C2-8 alkylene group and R1 and R2 are independently selected from hydrogen, C1-4 alkyl, C2-4 hydroxy-alkyl and C2-4 aminoalkyl, or R1 and R2 together form a C2-6 alkylene group which with the nitrogen atom to which R1 and R2 are attached forms a heterocyclic ring, or an N-oxide derivative thereof, and wherein the compound (I) or its N-oxide derivative is optionally in the form of an acid salt derived from an organic or inorganic acid. Also disclosed is a method of its production and its uses, including its use in analyzing a cell or biological material and detecting the emitted fluorescence signal.
    Type: Grant
    Filed: February 20, 2001
    Date of Patent: October 22, 2002
    Assignee: Biostatus Limited
    Inventors: Paul James Smith, Laurence Hylton Patterson